No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B

PloS One
Lai WeiAlexander J Thompson

Abstract

It has yet to be firmly established whether host IFNL3 (IL28B) genotype influences interferon responsiveness in patients with chronic hepatitis B. We investigated associations between single-nucleotide polymorphisms (SNPs) in the IFNL3 region and response to peginterferon alfa-2a in 701 patients enrolled in three large, randomized, international studies. Responses were defined as hepatitis B surface antigen (HBsAg) loss and/or hepatitis B e antigen (HBeAg) seroconversion plus hepatitis B virus (HBV) DNA <2000 IU/ml in HBeAg-positive patients, and HBsAg loss and/or HBV DNA <2000 IU/ml in HBeAg-negative patients (24 weeks after end of treatment). Associations between treatment response and the number of copies of the poor-response allele at three SNPs (rs8099917, rs12980275, rs12979860) were explored with logistic regression models in Asian and white patients. The HBeAg-positive and -negative populations comprised 465 (92% Asian, 50% HBV genotype C) and 236 (79% Asian, 41% HBV genotype C) patients, respectively, and had respective response rates of 26% and 47%. The IFNL3 genotype was strongly associated with ethnicity. There was no association between IFNL3 genotype and treatment response in HBeAg-positive or -negative patients. ...Continue Reading

References

Feb 12, 2004·European Journal of Human Genetics : EJHG·Louise HoskingChun-Fang Xu
May 28, 2004·The New England Journal of Medicine·Andrew J MuirUNKNOWN Atlantic Coast Hepatitis Treatment Group
Sep 17, 2004·The New England Journal of Medicine·Patrick MarcellinUNKNOWN Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group
Jul 1, 2005·The New England Journal of Medicine·George K K LauUNKNOWN Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group
Jan 16, 2009·The New England Journal of Medicine·Maribel Rodriguez-TorresUNKNOWN Latino Study Group
Sep 15, 2009·Nature Genetics·Vijayaprakash SuppiahJacob George
Sep 18, 2009·Nature·David L ThomasMary Carrington
Jul 20, 2010·Gastroenterology·Hans L TillmannUNKNOWN German Anti-D Study Group
Aug 31, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jason GrebelyUNKNOWN ATAHC Study Group
Oct 12, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Thomas J UrbanNezam Afdhal
Nov 3, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y-F LiawP Marcellin
Mar 23, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver
Apr 5, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Pietro LamperticoMassimo Colombo
Apr 28, 2012·Gastroenterology·Alexander J Thompson
May 26, 2012·Gastroenterology·Fred PoordadUNKNOWN SPRINT-2 and RESPOND-2 Investigators
Jan 11, 2013·Journal of Gastroenterology and Hepatology·Jacinta A HolmesAlexander J Thompson

❮ Previous
Next ❯

Citations

May 1, 2020·International Journal of Molecular Sciences·Hirayuki EnomotoShuhei Nishiguchi
Dec 19, 2020·Expert Review of Gastroenterology & Hepatology·Ming-Lun YehWan-Long Chuang

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
genotyping

Software Mentioned

SAS

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.